Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food nd Drug Administration's (FDA) Office of Orphan Products Development has granted orphan drug status to BioSante Pharmaceuticals' melanoma cancer vaccine as a treatment for stage IIb to IV melanoma.
Subscribe to our email newsletter
In total, the company has already received Orphan drug designation for vaccines for pancreatic cancer, acute myeloid leukemia and chronic myeloid leukemia.
BioSante Pharma president and CEO Stephen Simes said they continue to develop their vaccine portfolio in cooperation with the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
"Clinical trials of our cancer vaccines are being conducted to treat leukemia, breast cancer, and pancreatic cancer, among other cancer types," Simes said.